JMI Labs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

JMI Laboratories, founded in 2001 and based in North Liberty, Iowa, is a specialized contract research organization (CRO) and reference lab focused exclusively on infectious diseases and antimicrobial resistance. It operates as a high-value service provider, offering microbiology, surveillance, and molecular testing services essential for antimicrobial drug development from preclinical stages through post-marketing commitments. The company was acquired by Element Materials Technology, indicating its established reputation and integration into a larger scientific testing network. Its core business model is providing fee-for-service laboratory and consulting support, not developing its own therapeutic pipeline.

Infectious Disease

Technology Platform

Integrated microbiology service platform including global antimicrobial surveillance (SENTRY Program), CLIA-certified reference laboratory, molecular/genomic characterization, microbiome analysis, and GCLP-compliant clinical trial support.

Opportunities

The urgent global threat of antimicrobial resistance (AMR) drives continued demand for new drug development and surveillance, ensuring a need for JMI's specialized services.

Expansion into support for non-traditional antimicrobial therapies (e.g., phage, microbiome modulators) and leveraging its vast surveillance dataset for advanced analytics present growth avenues.

Integration with Element Materials Technology provides resources for geographic expansion and cross-selling of complementary testing services.

Risk Factors

The company's success is tied to the fragile antimicrobial R&D ecosystem, where many client biotechs face financial instability and high clinical failure rates, potentially reducing contract volume.

There is dependency on key scientific personnel whose expertise and industry relationships are core assets.

Competition from larger, full-service CROs and other specialty labs, though mitigated by JMI's strong reputation, remains a constant market factor.

Competitive Landscape

JMI competes with the central laboratory divisions of large, global Contract Research Organizations (CROs) like IQVIA and LabCorp, as well as other specialized infectious disease reference laboratories. Its primary competitive advantage is its deep, focused expertise in antimicrobial microbiology, decades of surveillance data from the SENTRY Program, and recognized regulatory experience, which create high barriers to entry and a strong reputation moat in a niche market.

More companies in Diagnostics & Precision Medicine →More companies in United States →